BioLineRx (NASDAQ:BLRX) Shares Pass Above 200 Day Moving Average – What’s Next?

BioLineRx Ltd. (NASDAQ:BLRX) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.86 and traded as high as $2.87. BioLineRx shares last traded at $2.7710, with a volume of 4,892 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioLineRx in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

BioLineRx Price Performance

The business’s 50-day moving average price is $3.01 and its 200 day moving average price is $2.86. The company has a market capitalization of $12.18 million, a P/E ratio of -1.45 and a beta of 1.54. The company has a quick ratio of 1.43, a current ratio of 1.58 and a debt-to-equity ratio of 0.16.

BioLineRx (NASDAQ:BLRX) last posted its earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.68. BioLineRx had a negative net margin of 563.70% and a negative return on equity of 37.73%. The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.34 million.

About BioLineRx

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.